Cargando…

KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population

BACKGROUND: KRAS is commonly mutated in non-small cell lung cancer (NSCLC); however, the prognostic and predictive impact of each G12 substitution has not been fully elucidated. The approval of specific G12C inhibitors has modified the idea of KRAS “undruggability”, and although the first-line stand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fancelli, Sara, Caliman, Enrico, Mazzoni, Francesca, Paglialunga, Luca, Gatta Michelet, Marta Rita, Lavacchi, Daniele, Berardi, Rossana, Mentrasti, Giulia, Metro, Giulio, Birocchi, Ilaria, Delmonte, Angelo, Priano, Ilaria, Comin, Camilla Eva, Castiglione, Francesca, Bartoli, Caterina, Voltolini, Luca, Pillozzi, Serena, Antonuzzo, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702560/ https://www.ncbi.nlm.nih.gov/pubmed/36452502 http://dx.doi.org/10.3389/fonc.2022.968064

Ejemplares similares

Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives
por: Fancelli, Sara, et al.
Publicado: (2021)

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
por: Lavacchi, Daniele, et al.
Publicado: (2022)

Induction Chemotherapy Followed by Pleurectomy Decortication and Hyperthermic Intraoperative Chemotherapy (HITHOC) for Early-Stage Epitheliod Malignant Pleural Mesothelioma—A Prospective Report
por: Bongiolatti, Stefano, et al.
Publicado: (2021)

Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study
por: Paderi, Agnese, et al.
Publicado: (2021)

Primary pleural epithelioid hemangioendothelioma: case report and review of the literature
por: Lavacchi, Daniele, et al.
Publicado: (2021)

Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients
por: Lavacchi, Daniele, et al.
Publicado: (2023)

Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment
por: Gambale, Elisabetta, et al.
Publicado: (2022)

REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing
por: Lavacchi, Daniele, et al.
Publicado: (2023)

KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation
por: Lastraioli, Elena, et al.
Publicado: (2021)

Alteration of the Nucleotide Excision Repair (NER) Pathway in Soft Tissue Sarcoma
por: Pasqui, Adriano, et al.
Publicado: (2022)

Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
por: Lavacchi, Daniele, et al.
Publicado: (2023)

Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)
por: Metro, Giulio, et al.
Publicado: (2022)

A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma
por: Lavacchi, Daniele, et al.
Publicado: (2018)

Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis
por: Paderi, Agnese, et al.
Publicado: (2021)

Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study
por: Salvianti, Francesca, et al.
Publicado: (2021)

KRAS Mutations Are Associated with Shortened Survival in Patients with Epithelioid Malignant Pleural Mesothelioma
por: Vannucchi, Margherita, et al.
Publicado: (2023)

Gastric and colonic metastasis from NSCLC: A very unusual case report
por: Catalano, Martina, et al.
Publicado: (2022)

Benefits and Limitations of a Multidisciplinary Approach in Cancer Patient Management
por: Berardi, Rossana, et al.
Publicado: (2020)

Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): Optimal Management
por: Mentrasti, Giulia, et al.
Publicado: (2020)

Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience
por: Lavacchi, Daniele, et al.
Publicado: (2021)

A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy
por: Hasic Telalovic, Jasminka, et al.
Publicado: (2021)

Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level
por: Pillozzi, Serena, et al.
Publicado: (2021)

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
por: Lavacchi, Daniele, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Non-small-cell lung cancer: how to manage EGFR-mutated disease
por: Pecci, Federica, et al.
Publicado: (2022)

Results of the observational prospective RealFLOT study
por: Giommoni, Elisa, et al.
Publicado: (2021)

Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature
por: Baglivo, Sara, et al.
Publicado: (2022)

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
por: Ricciuti, Biagio, et al.
Publicado: (2017)

The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

Liquid biopsy in colorectal cancer: No longer young, but not yet old
por: Roviello, Giandomenico, et al.
Publicado: (2022)

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
por: Canale, Matteo, et al.
Publicado: (2022)

Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer
por: Malentacchi, Francesca, et al.
Publicado: (2019)

High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis
por: Bronte, Giuseppe, et al.
Publicado: (2022)

Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer
por: Andrikou, Kalliopi, et al.
Publicado: (2023)

Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia
por: Giampieri, Riccardo, et al.
Publicado: (2019)

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
por: Ricciuti, Biagio, et al.
Publicado: (2022)

Classic and Follicular Variant of Papillary Thyroid Microcarcinoma: 2 Different Phenotypes Beyond Tumor Size
por: Sparano, Clotilde, et al.
Publicado: (2022)

Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
por: Ulivi, Paola, et al.
Publicado: (2021)

Luteinizing Hormone/Human Chorionic Gonadotropin Receptor Immunohistochemical Score Associated with Poor Prognosis in Endometrial Cancer Patients
por: Sorbi, Flavia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d04ao5a2bv2pqd4vh5f1mu0rsp